We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The Nan Fung Group’s venture capital firm Pivotal bioVenture Partners has raised a $150 million venture fund to help early-stage life science companies located within China.